Navigation Links
Beckman Coulter Announces First Quarter 2008 Results
Date:4/30/2008

ded, "We are improving our full year outlook based on our first quarter performance. Assuming stable currency, full year revenue growth should be in the range of 11% to 13%. We expect 2008 operating income margin to be 12% to 12.5%. The outlook for non-operating expense is approximately $12 to $13 million per quarter. Pretax profit growth should be 12% to 15%, with a tax rate between 29% and 30%. We are raising the low end of our outlook for earnings per diluted share. Consequently, we expect our EPS to be between $3.55 and $3.65 based on a share count of 64.5 million. EBITDA for the full year 2008 should be $580 to $630 million. Capital expenditures are expected to be $290 to $310 million, and depreciation and amortization should be between $240 and $260 million.

"We're encouraged by the progress our company is making in 2008. We continue to significantly outperform the market in clinical diagnostics with strength in consultative selling, responsive service and innovative automation leadership. Clearly, we are making the improvements and investments necessary to achieve our revenue and earnings goals," he said.

Investor Conference Call

As previously announced, there will be a conference call today, Wednesday, April 30, 2008 at 8:30 am ET to discuss the first quarter ended March 31, 2008 results. The call will be webcast live and is accessible to all investors through Beckman Coulter's website at http://www.beckmancoulter.com or at http://www.streetevents.com. When accessing the webcast through the Beckman Coulter site, select "go to IR" under Investor Relations and find the call listed under "What's Ahead." The webcast will be archived on both websites for future on-demand replay through Friday, May 30, 2008.

About Beckman Coulter

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related biology technology :

1. Beckman Coulter Acquires Rights to Hepatitis C Virus
2. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
5. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
6. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
7. Beckman Coulter to Present at the JPMorgan Healthcare Conference
8. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
9. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
10. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... will be Centerpiece to Expansion of ... Radiation Oncology Facility, ... ), a global leader in the field of radiosurgery,today announced ... Robotic Radiosurgery System to further expand treatment,offerings for its nationally ...
... 24 United,Therapeutics Corporation (Nasdaq: UTHR ) ... quarter financial results before the open of market,on ... host a half-hour teleconference on Thursday,July 31, 2008, ... accessible,by dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A ...
... VEDBAEK, Denmark, July 24 Frost & Sullivan,has announced ... 2008 Growth,Strategy Leadership Award in the molecular diagnostic market. ... the molecular diagnostic,market., Exiqon was selected for this ... leader in the field of in vitro therapy selection,testing ...
Cached Biology Technology:St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 2St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 3St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 4Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 2Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 3
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... A variety of end products including jet fuel, gasoline, ... existing refineries and combinations of coal and refinery by-products, ... idea is based on the coal-to-jet fuel work that ... Caroline E. Burgess Clifford, research associate at Penn State,s ...
... tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based ... transfer radical polymerization (ATRP), which will ultimately enable ... the target and to dispense the drug in ... 200 nanometers in diameter possess many unique ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
Cached Biology News:Coal-based fuels and products hit the refinery 2Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs 2Truly sick or simply scared? 2
... I, Wild Type Liquid. In 100 ... 200 µM EDTA, 20% glycerol, pH 7.9. AVOID ... is a monomeric protein of 765 amino acids ... relaxation of both positive and negative supercoiled DNAs ...
Request Info...
... in a 3'-> 5' direction from a ... of single-stranded DNA. Under defined reaction conditions, ... a uniform rate yielding predictable and reproducible ... of deoxyribonucleotides by Exonuclease III is dependent ...
... an endoribonuclease, the RNA strand of ... origin, e.g. that of phage FX174, ... x poly(dT). RNase H produces ribonucleotides ... no activity is detected with polyribonucleotides ...
Biology Products: